Diabetes Care review argues for precision prescribing of GLP-1 receptor agonists
The November commentary addresses how clinicians might match individual patients to specific incretin agents for glucose lowering.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 20 19:00 ETSource: Diabetes care
The wire
- 01Diabetes Care published a piece by Umapathysivam and colleagues on moving GLP-1 receptor agonist prescribing toward a precision-medicine framework for glucose lowering.
- 02Prescribers choosing among incretin agents for type 2 diabetes are the intended audience, as agent-level differences in glycemic response remain poorly characterized.
- 03Only the title and citation are available; the specific recommendations, evidence base and any predictive markers proposed are not detailed here.
From the source
Read at pubmed.ncbi.nlm.nih.govToward Precision Prescribing of GLP-1 Receptor Agonists for Glucose Lowering
Diabetes care · 2026 Nov 1 · Umapathysivam MM et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42900828/
